Amedeo Smart

Free Medical Literature Service



Colorectal Neoplasms

  Free Subscription

Articles published in
Eur J Cancer
    December 2017
  1. VAN CUTSEM E, Mayer RJ, Laurent S, Winkler R, et al
    The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Eur J Cancer. 2017;90:63-72.
    >> Share

    November 2017
  2. MODEST DP, Denecke T, Pratschke J, Ricard I, et al
    Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Eur J Cancer. 2017;88:77-86.
    >> Share

  3. COHEN R, Buhard O, Cervera P, Hain E, et al
    Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Eur J Cancer. 2017;86:266-274.
    >> Share

    October 2017
  4. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Eur J Cancer. 2017;86:197-206.
    >> Share

  5. KEIKES L, Koopman M, Tanis PJ, Lemmens VEPP, et al
    Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.
    Eur J Cancer. 2017;86:166-177.
    >> Share

  6. PREVOSTEL C, Blache P
    The dose-dependent effect of SOX9 and its incidence in colorectal cancer.
    Eur J Cancer. 2017;86:150-157.
    >> Share

  7. MALKA D, Rotolo F, Boige V
    First-line treatment in metastatic colorectal cancer: Important or crucial?
    Eur J Cancer. 2017;84:363-366.
    >> Share

    September 2017
  8. TURATI F, Bravi F, Di Maso M, Bosetti C, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk.
    Eur J Cancer. 2017;85:86-94.
    >> Share

    August 2017
  9. MODEST DP, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
    Eur J Cancer. 2017;84:262-269.
    >> Share

  10. MAY-WILSON S, Sud A, Law PJ, Palin K, et al
    Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
    Eur J Cancer. 2017;84:228-238.
    >> Share

  11. STINTZING S, Tejpar S, Gibbs P, Thiebach L, et al
    Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.
    Eur J Cancer. 2017;84:69-80.
    >> Share

    July 2017
  12. TOPI G, Ehrnstrom R, Jirstrom K, Palmquist I, et al
    Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer.
    Eur J Cancer. 2017;83:279-289.
    >> Share

  13. CASCINU S, Rosati G, Nasti G, Lonardi S, et al
    Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase
    Eur J Cancer. 2017;83:106-115.
    >> Share

  14. KATONA BW, Yang YX
    Colorectal cancer risk associated with the CHEK2 1100delC variant.
    Eur J Cancer. 2017;83:103-105.
    >> Share

  15. STINTZING S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, et al
    Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Eur J Cancer. 2017;79:50-60.
    >> Share

    June 2017
  16. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;82:92-102.
    >> Share

  17. EMILE JF, Julie C, Le Malicot K, Lepage C, et al
    Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Eur J Cancer. 2017;82:16-24.
    >> Share

  18. CARRATO A, Abad A, Massuti B, Gravalos C, et al
    First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Eur J Cancer. 2017;81:191-202.
    >> Share

  19. YAMANO T, Yamauchi S, Kimura K, Babaya A, et al
    Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.
    Eur J Cancer. 2017;81:90-101.
    >> Share

  20. THOMSEN M, Guren MG, Skovlund E, Glimelius B, et al
    Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
    Eur J Cancer. 2017;81:26-35.
    >> Share

  21. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    >> Share

  22. YOSHINO T, Obermannova R, Bodoky G, Garcia-Carbonero R, et al
    Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Eur J Cancer. 2017;78:61-69.
    >> Share

  23. ADAM R, Yi B, Innominato PF, Barroso E, et al
    Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
    Eur J Cancer. 2017;78:7-15.
    >> Share

    April 2017
  24. ROVERS KP, Simkens GA, Vissers PA, Lemmens VE, et al
    Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.
    Eur J Cancer. 2017;75:132-140.
    >> Share

    March 2017
  25. FROUWS MA, Rademaker E, Bastiaannet E, van Herk-Sukel MP, et al
    The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
    Eur J Cancer. 2017;77:24-30.
    >> Share

  26. BERGER MD, Yamauchi S, Cao S, Hanna DL, et al
    Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Eur J Cancer. 2017;77:13-20.
    >> Share

  27. HOLCH JW, Heinemann V
    Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients.
    Eur J Cancer. 2017;77:1-2.
    >> Share

  28. KWAKMAN JJ, Simkens LH, Mol L, Kok WE, et al
    Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Eur J Cancer. 2017;76:93-99.
    >> Share

  29. DEL RIO M, Mollevi C, Bibeau F, Vie N, et al
    Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    Eur J Cancer. 2017;76:68-75.
    >> Share

  30. TREASURE T, Williams NR
    Best available evidence related to clinical benefit of surgical resection in multimodality treatment of metastatic colorectal cancer indicates that a randomised controlled trial is warranted.
    Eur J Cancer. 2017;75:310-312.
    >> Share

    February 2017
  31. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    >> Share

  32. FRANKEN MD, van Rooijen EM, May AM, Koffijberg H, et al
    Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Eur J Cancer. 2017;75:204-212.
    >> Share

  33. HUGEN N, Nagtegaal ID
    Distinct metastatic patterns in colorectal cancer patients based on primary tumour location.
    Eur J Cancer. 2017;75:3-4.
    >> Share

  34. PAPAMICHAEL D, Aapro M
    Geriatric factors and outcomes in metastatic colorectal cancer.
    Eur J Cancer. 2017 Feb 10. pii: S0959-8049(16)32566.
    >> Share

  35. MECHERA R, Schuster T, Rosenberg R, Speich B, et al
    Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2017;72:84-94.
    >> Share

  36. SCHAFFAR R, Rachet B, Belot A, Woods LM, et al
    Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.
    Eur J Cancer. 2017;72:78-83.
    >> Share

  37. FRIN AC, Evesque L, Gal J, Benezery K, et al
    Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.
    Eur J Cancer. 2017;72:124-136.
    >> Share

    January 2017
  38. MODEST DP, Neumann UP, Pratschke J
    FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    Eur J Cancer. 2017 Jan 9. pii: S0959-8049(16)33085.
    >> Share

  39. SARTORE-BIANCHI A, Pietrantonio F, Amatu A, Milione M, et al
    Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Eur J Cancer. 2017;71:43-50.
    >> Share

  40. 'T LAM-BOER J, van der Stok EP, Huiskens J, Verhoeven RH, et al
    Regional and inter-hospital differences in the utilisation of liver surgery for patients with synchronous colorectal liver metastases in the Netherlands.
    Eur J Cancer. 2017;71:109-116.
    >> Share

  41. CHAN AK, Siriwardena AK
    Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer.
    Eur J Cancer. 2017;71:51-52.
    >> Share

    December 2016
  42. CREMOLINI C, Casagrande M, Loupakis F, Aprile G, et al
    Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Eur J Cancer. 2016 Dec 13. pii: S0959-8049(16)32534.
    >> Share

    November 2016
  43. HOLCH JW, Ricard I, Stintzing S, Modest DP, et al
    The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
    Eur J Cancer. 2016;70:87-98.
    >> Share

  44. DUCREUX M, Pignon JP
    Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?
    Eur J Cancer. 2016;69:178-179.
    >> Share

  45. APARICIO T, Gargot D, Teillet L, Maillard E, et al
    Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    Eur J Cancer. 2016 Nov 5. pii: S0959-8049(16)32475.
    >> Share

  46. ROTTENBERG Y, Ratzon NZ, Cohen M, Hubert A, et al
    Unemployment risk at 2 and 4 years following colorectal cancer diagnosis: a population based study.
    Eur J Cancer. 2016;69:70-76.
    >> Share

  47. GOEY KK, 't Lam-Boer J, de Wilt JH, Punt CJ, et al
    Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
    Eur J Cancer. 2016;69:166-177.
    >> Share

    October 2016
  48. BOUCHAHDA M, Boige V, Smith D, Karaboue A, et al
    Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Eur J Cancer. 2016;68:163-172.
    >> Share

  49. PRICE T, Kim TW, Li J, Cascinu S, et al
    Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Eur J Cancer. 2016;68:51-59.
    >> Share

  50. ZHAO Y, Fan D, Ru B, Cheng KW, et al
    6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Eur J Cancer. 2016;68:38-50.
    >> Share

    September 2016
  51. HEINEMANN V, Rivera F, O'Neil BH, Stintzing S, et al
    A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2016;67:11-20.
    >> Share

    August 2016
  52. MOL L, Ottevanger PB, Koopman M, Punt CJ, et al
    The prognostic value of WHO performance status in relation to quality of life in advanced colorectal cancer patients.
    Eur J Cancer. 2016;66:138-143.
    >> Share

    July 2016
  53. CABALLERO-BANOS M, Benitez-Ribas D, Tabera J, Varea S, et al
    Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
    Eur J Cancer. 2016;64:167-174.
    >> Share

    June 2016
  54. BREUGOM AJ, Bastiaannet E, Boelens PG, Iversen LH, et al
    Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.
    Eur J Cancer. 2016;63:110-117.
    >> Share

    May 2016
  55. BANDO H, Doi T, Muro K, Yasui H, et al
    A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Eur J Cancer. 2016;62:46-53.
    >> Share

  56. LOGANADANE G, Servagi-Vernat S, Schernberg A, Schlienger M, et al
    Chemoradiation in rectal squamous cell carcinoma: Bi-institutional case series.
    Eur J Cancer. 2016;58:83-9.
    >> Share

    March 2016
  57. MCLACHLAN SA, Fisher RJ, Zalcberg J, Solomon M, et al
    The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04).
    Eur J Cancer. 2016;55:15-26.
    >> Share

  58. HAAGENSEN EJ, Thomas HD, Mudd C, Tsonou E, et al
    Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Eur J Cancer. 2016;56:69-76.
    >> Share

    January 2016
  59. HELDER-WOOLDERINK JM, Blok EA, Vasen HF, Hollema H, et al
    Ovarian cancer in Lynch syndrome; a systematic review.
    Eur J Cancer. 2016;55:65-73.
    >> Share

  60. FORMICA V, Formica D, Formica G
    The 'death pace' in the CO.17 trial.
    Eur J Cancer. 2016;53:1-4.
    >> Share

  61. CASHIN PH, Mahteme H, Spang N, Syk I, et al
    Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    Eur J Cancer. 2016;53:155-62.
    >> Share

  62. NOREN A, Eriksson HG, Olsson LI
    Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study.
    Eur J Cancer. 2016;53:105-14.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016